Archives: Agenda

• Sharing real examples of decisions that led to delays inefficiencies or trial failure
• Understanding early warning signs that were missed or ignored
• Identifying what should have been done differently in hindsight
• Applying these lessons to improve future trial design and execution

3 x Biopharma panel seats available

1 x Vendor panel seat available

• Insights from the Nordic Patient Empowerment Survey (Nordic Rare Disease Summit 2025) and the Danish Rare Disease Survey (Guldkundeunders gelsen 2025) and their relevance for clinical trial design and patient engagement
• Building trust and improving communication to support participation in healthcare and clinical research
• Understanding the practical barriers faced by people living with rare diseases and how they may influence clinical trial participation
• Moving from consultation to partnership: patient perspectives on involvement and decision-making throughout the research journey
• Leveraging insights from Nordic patient organisations to better understand patient needs and priorities in rare disease research

• Exploring initiatives like Trial Nation
• Understanding funding structures
• Deciding when they add value

• Defining clear roles and responsibilities between sponsor and CRO to avoid duplication and gaps
• Identifying what sponsors should actively oversee versus what can be delegated with confidence
• Setting meaningful KPIs and oversight models that focus on risk rather than excessive monitoring
• Improving communication and escalation pathways to prevent delays and misalignment
• Avoiding common mistakes that lead to over-control increased workload and inefficiencies

• Comparing timelines and setup across the UK EU and other key regions
• Understanding trade-offs between speed cost quality and patient access
• Deciding how to prioritise regions based on trial type and strategy

1 x Biopharma panel seat available

1 x Vendor panel seat available